NCT07511205RECRUITINGanonymous

A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1043 Following Single and Multiple Ascending Doses Via Subcutaneous and/or Intravenous Administration in Healthy Adult Participants Living With Overweight and/or Obesity.

Sponsor

Source record

AstraZeneca

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

AZD1043 is designed to target mechanisms associated with obesity and metabolic disorders, although specific molecular targets have not been disclosed in the provided data.

Indication / condition

AI-normalized

Healthy Participants

Intervention

Source record

AZD1043, Placebo

Related intelligence directories

Indication directory: Healthy Participants Modality directory: small molecule Target directory: AZD1043 is designed to target mechanisms associated with obesity and metabolic disorders

Source & freshness

Source record

NCT ID

NCT07511205

Original source

ClinicalTrials.gov

Source last updated

Detailed source ingestion pending.

Ingested at

Jun 25, 2026

Internal sync

Jun 25, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT07511205

Title

A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1043 Following Single and Multiple Ascending Doses Via Subcutaneous and/or Intravenous Administration in Healthy Adult Participants Living With Overweight and/or Obesity.

Sponsor

AstraZeneca

Status

RECRUITING

Phase

Phase 1

Condition raw

Healthy Participants, Obesity

Condition normalized

Healthy Participants, Obesity

Modality raw

small molecule

Modality normalized

small molecule

Target raw

AZD1043 is designed to target mechanisms associated with obesity and metabolic disorders, although specific molecular targets have not been disclosed in the provided data.

Target normalized

AZD1043 is designed to target mechanisms associated with obesity and metabolic disorders, although specific molecular targets have not been disclosed in the provided data.

Interventions

AZD1043, Placebo

Public preview

Source record

AZD1043 is currently in Phase 1 clinical trials, focusing on safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults with overweight and obesity. The study includes diverse cohorts, specifically targeting Japanese and Chinese populations, which may enhance its marketability in Asia. Given the rising prevalence of obesity globally, AZD1043 could address a significant unmet need in weight management therapies. AstraZeneca's collaboration with Parexel for this trial indicates a strategic approach to streamline clinical development. The competitive landscape includes other obesity treatments, but AZD1043's unique profile may offer differentiation. Diligence should focus on regulatory pathways, potential market entry timelines, and the evolving landscape of obesity management therapies.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1043 Following Single and Multiple Ascending Doses Via Subcutaneous and/or Intravenous Administration in Healthy Adult Participants Living With Overweight and/or Obesity.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 25, 2026

Report code

NCT07511205-Jun 25, 2026

NCT ID

NCT07511205

Status

RECRUITING

Phase

Phase 1

Sponsor

AstraZeneca

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedDetailed source ingestion pending.

Internal syncJun 25, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07511205

Indication

Healthy Participants

Modality

small molecule

Target

AZD1043 is designed to target mechanisms associated with obesity and metabolic disorders, although specific molecular targets have not been disclosed in the provided data.

Intervention

AZD1043, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.